Log In Sign up
The largest database of trusted experimental protocols

Amg510

Manufactured by MedChemExpress
Visit Supplier
Sourced in United States, China

AMG510 is a lab equipment product manufactured by MedChemExpress. It is a high-performance instrument designed for biochemical and biophysical research applications. The core function of AMG510 is to facilitate precise and accurate measurements and analyses of various biomolecules and chemical compounds.

Automatically generated - may contain errors

Lab products found in correlation

Gefitinib, by Selleck Chemicals (3 mentions) Mrtx849, by MedChemExpress (3 mentions) Sch772984, by MedChemExpress (3 mentions) Bgj398, by Selleck Chemicals (2 mentions) Trametinib, by Selleck Chemicals (2 mentions) Rmc 4550, by Selleck Chemicals (2 mentions) Rpmi 1640, by Merck Group (2 mentions) Ars 1620, by Selleck Chemicals (2 mentions) Selumetinib, by Thermo Fisher Scientific (2 mentions) Nocodazol, by Merck Group (2 mentions) Afatinib, by Selleck Chemicals (2 mentions) Erlotinib, by Selleck Chemicals (2 mentions) Lapatinib, by Selleck Chemicals (2 mentions) Ly3009120, by Selleck Chemicals (2 mentions) Shp099, by Selleck Chemicals (2 mentions) Cp 724714, by Merck Group (2 mentions) Epidermal growth factor (egf), by Thermo Fisher Scientific (2 mentions) Ro 3306, by Bio-Techne (2 mentions) Phorbol myristate acetate (pma), by Merck Group (2 mentions) Imatinib, by Selleck Chemicals (1 mentions)

14 protocols using amg510

1

Dose-Dependent Anti-Tumor Effects of AMG510

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-tumor drug AMG510 was applied at the final concentration of 0.001 μM, 0.005 μM, 0.01 μM, 0.05 μM, 0.1 μM, 0.5 μM, 1 μM and 5 μM. The AMG510 (MedChemExpress, Shanghai, China) was dissolved according to the manufacturer’s instructions and 100× working solutions were prepared with DMSO. A 1‰ DMSO treatment was used as control.
Huang M., Hou W., Zhang J., Li M., Zhang Z., Li X., Chen Z., Wang C, & Yang L. (2022). Evaluation of AMG510 Therapy on KRAS-Mutant Non–Small Cell Lung Cancer and Colorectal Cancer Cell Using a 3D Invasive Tumor Spheroid System under Normoxia and Hypoxia. Bioengineering, 9(12), 792.
+ Open protocol
+ Expand
2

Drug Resistance Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Puromycin was purchased from InvivoGen (catalog # ant-pr-1) and used at 1.5 μg/mL. Geneticin (G418) was purchased from ThermoFisher Scientific (catalog # 11811031) and used at 800 μg/mL. Doxycycline was purchased from MilliporeSigma (catalog # D9891) and used at 1 μg/mL unless otherwise stated. Compound B was synthesized by Daiichi-Sankyo and used at 500 nM to identify drug-resistant cells. Gefitinib was purchased from Selleck Chemicals (catalog # S1025) and used at 1 μM to identify drug-resistant cells. Osimertinib was purchased from Selleck Chemicals (catalog # S7297) and used at 100 nM to identify drug-resistant cells. Imatinib was purchased from Selleck Chemicals (catalog # S2475) and used at 1 μM to identify drug-resistant cells. AMG 510 was purchased from MedChemExpress (catalog # HY-114277) and used at 1 μM to identify drug-resistant cells. MRTX849 was purchased from SelleckChemicals (catalog # S8884).
Yenerall P., Kollipara R.K., Avila K., Peyton M., Eide C.A., Bottomly D., McWeeney S.K., Liu Y., Westover K.D., Druker B.J., Minna J.D, & Kittler R. (2021). Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research, 81(18), 4685-4695.
+ Open protocol
+ Expand
3

Authentication and Culture of Cell Lines for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lines were obtained from ATCC, Millipore Sigma or the Center for Molecular Therapeutics at the MGH Cancer Center (Boston, MA) (Crystal et al., 2014 (link)), which routinely performs cell line authentication testing by SNP and short tandem repeat analysis, and maintained in DMEM/F12 or RPMI 1640 supplemented with 10% fetal calf serum, and were not cultured longer than 6 months after receipt from cell banks. AMG 510 and MRTX849 used for in vitro and in vivo studies were purchased from MedChemExpress and ARS-1620, RMC-4550, BGJ398, and trametinib used for in vitro studies were purchased from Selleckchem. RM-018 used for in vitro studies and RMC-4550 used in in vivo studies were kindly provided by Revolution Medicines. Panitumumab was obtained from McKesson Pharmaceuticals.
Ryan M.B., Coker O., Sorokin A., Fella K., Barnes H., Wong E., Kanikarla P., Gao F., Zhang Y., Zhou L., Kopetz S, & Corcoran R.B. (2022). KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell reports, 39(12), 110993.
+ Open protocol
+ Expand
4

Assessing Kinase Inhibitor Efficacy

Check if the same lab product or an alternative is used in the 5 most similar protocols
EGF was from Invitrogen; selumetinib, afatinib, lapatinib, lapatinib, gefitinib, erlotinib, SHP099 and LY3009120 were from SelleckChem; SCH772984 was from MedChem Express; PMA, nocodazol and CP-724714 were from Sigma-Aldrich; RO-3306 was from Tocris Bioscience; AMG-510 was from MedChemExpress.
Ponsioen B., Post J.B., des Amorie J.R., Laskaris D., van Ineveld R.L., Kersten S., Bertotti A., Sassi F., Sipieter F., Cappe B., Mertens S., Verlaan-Klink I., Boj S.F., Vries R.G., Rehmann H., Vandenabeele P., Riquet F.B., Trusolino L., Bos J.L, & Snippert H.J. (2021). Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signaling. Nature cell biology, 23(4), 377-390.
+ Open protocol
+ Expand
5

Synergistic Drug Combination Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fifteen-hundred cells were seeded on a 96-well plate 24 h before drug treatment. The specific drugs used were AMG510 (MedChemExpress, USA, #HY-114277), GSK126 (Selleckchem, Houston, TX, USA, #S7061), and DS (DS18561882) (MedChemExpress, Monmouth Junction, NJ, USA, HY-130251). Cells were treated with indicated concentrations for indicated time periods. For synergistic effect assays, two inhibitors were combined in a series of nine increasing concentrations. Inhibitor concentrations ranged from 0 to 25 μM for AMG510, 0 to 20 μM for GSK126, and 0 to 100 μM for DS. In corresponding control groups, an equivalent amount of DMSO was added. After 72 h treatment, cell viability was analyzed using MTS, as described above. Drug synergy was evaluated using CompuSyn software (ComboSyn Inc, New York, NY, USA) for the combination index (CI) value calculations. CI values: antagonism (CI > 1.1), additive effect (CI < 1.1 and CI > 0.9), and synergism (CI < 0.9) [57 (link)].
Li Y., Elakad O., Yao S., von Hammerstein-Equord A., Hinterthaner M., Danner B.C., Ferrai C., Ströbel P., Küffer S, & Bohnenberger H. (2022). Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. Metabolites, 12(7), 652.
+ Open protocol
+ Expand
6

ALK Inhibitor Compounds Procurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crizotinib (PF-02341066), brigatinib (AP26113), and lorlatinib (PF-06463922) were purchased from Shanghai Biochempartner (Shanghai, Chaina). Gilteritinib (ASP2215) was purchased from Shanghai Biochempartner and Biovision (Milpitas, CA, USA). Alectinib (CH5424802) and ceritinib (LDK378) were purchased from ActiveBiochem (Kowloon, Hong Kong). Entrectinib (RXDX-101) and AMG510 were purchased from Medchem Express (Monmouth Junction, NJ, USA). Afatinib (BIBW2992) was purchased from ChemieTek (Indianapolis, IN, USA). Trametinib (GSK1120212) was purchased from AdooQ BioScience (Irvine, CA, USA). Brigatinib was dissolved in ethanol for in vitro experiments, and the other drugs were dissolved in dimethyl sulfoxide (DMSO).
Mizuta H., Okada K., Araki M., Adachi J., Takemoto A., Kutkowska J., Maruyama K., Yanagitani N., Oh-hara T., Watanabe K., Tamai K., Friboulet L., Katayama K., Ma B., Sasakura Y., Sagae Y., Kukimoto-Niino M., Shirouzu M., Takagi S., Simizu S., Nishio M., Okuno Y., Fujita N, & Katayama R. (2021). Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature Communications, 12, 1261.
+ Open protocol
+ Expand
7

Comprehensive Ferroptosis Modulation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blasticidin (AppliChem GmbH), RSL3 (Selleckchem), ML210 (Tocris), ML162 (Caymann), Erastin (Biomol), Sulfasalazine (SAS) (MedChemExpress), Imidazole Ketone Erastin (IKE) (Sellekchem), Ferrostatin-1 (Sigma Aldrich), Liproxstatin-1 (Biozol), Necrostatin-1s (Abcam), zVAD (ENZO), iFSP1 (Cayman Chemicals), Tert-butylhydroquinone (TBHQ) (Sellekchem), AMG510 (MedChemExpress), ARS1620 (Chemgood), PD184352 (Sigma Aldrich), MK2206 (Sellekchem), DRAQ7 (Biolegend), BODIPY C11 (Invitrogen), H2DCFDA (Invitrogen), Dharmafect I (Dharmacon), Puromycin (Sigma), Doxycycline hydrochloride (Alfa Aesar), 4-hydroxy-tamoxifen (4OHT) (Sigma), Polybrene (Merck), CaCl2 (Sigma Aldrich), HBS (Sigma Aldrich), propidium iodide (Sigma).
Müller F., Lim J.K., Bebber C.M., Seidel E., Tishina S., Dahlhaus A., Stroh J., Beck J., Yapici F.I., Nakayama K., Torres Fernández L., Brägelmann J., Leprivier G, & von Karstedt S. (2022). Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Cell Death and Differentiation, 30(2), 442-456.
+ Open protocol
+ Expand
8

AMG 510 Treatment in H358 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
H358 cells were seeded at 20% confluency into 58-cm2 dishes with complete culture medium and, depending on the experiment, 0.1% (vol/vol) DMSO vehicle or 0.12 μM AMG 510 (MedChemExpress, HY-114277).
Niu Y., Ferreira Azevedo C.A., Li X., Kamali E., Haagen Nielsen O., Storgaard Sørensen C, & Frödin M. (2022). Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. Nature Genetics, 54(12), 1983-1993.
+ Open protocol
+ Expand
9

Multimodal Analysis of Oncogenic Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (#9101), ERK, Phospho-STAT3 (Tyr705) (#9145), STAT3, Phospho-p90RSK, Phospho-S6 Ribosomal Protein (Ser235/236), p-MEK, Phospho-IRS-1 (Ser302), IRS1, GAPDH antibodies and the bead-conjugated rabbit anti-phosphotyrosine (P-Tyr-1000) were purchased from Cell signaling technology. AZD6244, PLX4032 were purchased from Selleck. AMG-510, MRTX-1257 were purchased from MedChemExpress (MCE). Atorvastatin (calcium salt) (Item No. 10493) was from Cayman chemical. Insulin, MβCD and FITC-CTXb were from Sigma.
Wang X.D., Kim C., Zhang Y., Rindhe S., Cobb M.H, & Yu Y. (2021). Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition. Journal of proteome research, 20(12), 5379-5391.
+ Open protocol
+ Expand
10

Authentication and Culture of Cell Lines for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lines were obtained from ATCC, Millipore Sigma or the Center for Molecular Therapeutics at the MGH Cancer Center (Boston, MA) (Crystal et al., 2014 (link)), which routinely performs cell line authentication testing by SNP and short tandem repeat analysis, and maintained in DMEM/F12 or RPMI 1640 supplemented with 10% fetal calf serum, and were not cultured longer than 6 months after receipt from cell banks. AMG 510 and MRTX849 used for in vitro and in vivo studies were purchased from MedChemExpress and ARS-1620, RMC-4550, BGJ398, and trametinib used for in vitro studies were purchased from Selleckchem. RM-018 used for in vitro studies and RMC-4550 used in in vivo studies were kindly provided by Revolution Medicines. Panitumumab was obtained from McKesson Pharmaceuticals.
Ryan M.B., Coker O., Sorokin A., Fella K., Barnes H., Wong E., Kanikarla P., Gao F., Zhang Y., Zhou L., Kopetz S, & Corcoran R.B. (2022). KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell reports, 39(12), 110993.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!